{
    "root": "9185be55-73dd-4f69-b084-468cc2c97f73",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": {
        "text": "Risperidone"
    },
    "value": "20250505",
    "ingredients": [
        {
            "name": "Risperidone",
            "code": "L6UH7ZF8HC"
        },
        {
            "name": "Magnesium Aluminometasilicate Type I-a",
            "code": "7LVU907546"
        },
        {
            "name": "Aspartame",
            "code": "Z0H242BBR1"
        },
        {
            "name": "Silicon Dioxide",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "Hydroxypropyl Cellulose, Low Substituted",
            "code": "2165RE0K14"
        },
        {
            "name": "Sodium Stearyl Fumarate",
            "code": "7CV7WJK4UI"
        },
        {
            "name": "Dimethylaminoethyl Methacrylate - Butyl Methacrylate - Methyl Methacrylate Copolymer",
            "code": "905HNO1SIH"
        },
        {
            "name": "Talc",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "Sodium Lauryl Sulfate",
            "code": "368GB5141J"
        },
        {
            "name": "Acesulfame Potassium",
            "code": "23OV73Q5G9"
        },
        {
            "name": "Mannitol",
            "code": "3OWL53L36A"
        },
        {
            "name": "Sodium Chloride",
            "code": "451W47IQ8X"
        },
        {
            "name": "Peppermint",
            "code": "V95R5KMY2B"
        },
        {
            "name": "Ferric Oxide Yellow",
            "code": "EX438O2MRT"
        },
        {
            "name": "Fd&c Blue No. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "Fd&c Yellow No. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "Ferric Oxide Red",
            "code": "1K09F3G675"
        }
    ],
    "indications": "Risperidone orally disintegrating tablets are atypical antipsychotic indicated for: Treatment of schizophrenia ( 1.1 ) As monotherapy or adjunctive therapy with lithium or valproate, for the treatment of acute manic or mixed episodes associated with Bipolar I Disorder ( 1.2) Treatment of irritability associated with autistic disorder ( 1.3 )",
    "contraindications": "Table 1. Recommended Daily Dosage by Indication\n                  \n                  \n                     \n                        \n                           \n                           \n                              Initial \n                              Dose\n                           \n                           \n                              Titration \n                              (Increments)\n                           \n                           \n                              Target \n                              Dose\n                           \n                           \n                              Effective \n                              Dose Range\n                           \n                        \n                        \n                           \n                              Schizophrenia: adults (2.1)\n                           \n                            2 mg \n                            1 to 2 mg \n                            4 to 8 mg \n                            4 to 16 mg \n                        \n                        \n                           \n                              Schizophrenia: adolescents (2.2)\n                           \n                            0.5 mg \n                            0.5 to 1 mg \n                            3 mg \n                            1 to 6 mg \n                        \n                        \n                           \n                              Bipolar mania: adults (2.2)\n                           \n                            2 to 3 mg \n                            1 mg \n                            1 to 6 mg \n                            1 to 6 mg \n                        \n                        \n                           \n                              Bipolar mania: children and adolescents (2.2)\n                           \n                            0.5 mg \n                            0.5 to 1 mg \n                            1 to 2.5 mg \n                            1 to 6 mg \n                        \n                        \n                           \n                              Irritability in autistic disorder (2.3)\n                           \n                            0.25 mg Can increase to 0.5 mg by Day 4: (body weight less than 20 kg)   \n                              0.5 mg  Can increase to 1 mg by Day 4: (body weight greater than or equal to 20 kg) \n                            After Day 4, at intervals of > 2 weeks: 0.25 mg (body weight less than 20 kg) \n                              0.5 mg (body weight greater than or equal to 20 kg) \n                            0.5 mg: (body weight less than 20 kg)       \n                              1 mg: (body weight greater than or equal to 20 kg) \n                            0.5 to 3 mg \n                        \n                     \n                  \n                  Severe Renal and Hepatic Impairment in Adults: use a lower starting dose of 0.5 mg twice daily. May increase to dosages above 1.5 mg twice daily at intervals of one week or longer.",
    "warningsAndPrecautions": null,
    "adverseReactions": "Risperidone is contraindicated in patients with a known hypersensitivity to either risperidone or paliperidone, or to any of the excipients in the risperidone formulation. Hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported in patients treated with risperidone and in patients treated with paliperidone. Paliperidone is a metabolite of risperidone."
}